Targeting Inflammation in Osteoarthritis Pain: A Phenotype-Driven Approach
Воздействие на воспаление при боли, обусловленной остеоартритом: фенотип-ориентированный подход
2026-10-01
SCID: 54.1/s53bd6d4
Discuss with AI
imaging-defined synovitisinflammatory biomarkersinflammatory phenotypemethotrexateosteoarthritis pain
Figures from the paper
Abstract (AI)
Background: Osteoarthritis (OA) is a chronic joint disease marked by the progressive loss of articular cartilage and associated inflammatory processes, which can lead to significant pain and disability. However, the heterogeneous nature of OA has limited the effectiveness of many anti-inflammatory interventions, highlighting the need for phenotype-driven therapeutic strategies. Methods: This narrative review was conducted by searching PubMed, Web of Science, and Google Scholar from inception to June 2025. Predefined keywords included "osteoarthritis", "inflammation", "pain", "synovitis", "effusion", "treatment", "therapy" and "clinical trials". Additional relevant publications were identified through citation tracking of the included papers. Results: Our analysis of recent randomized clinical trials (RCTs) reveals a clear divergence in therapeutic efficacy, while targeted biologics (eg, TNF-α inhibitors like adalimumab and IL-1 blockers such as lutikizumab) have largely failed to meet primary pain endpoints in unselected populations, broad-spectrum immunomodulators like methotrexate (MTX) show significant promise, particularly in reducing pain and stiffness for the inflammatory phenotype. Furthermore, emerging evidence suggests that intra-articular (IA) treatments and phenotype-driven stratifications are essential to overcoming the current "one-size-fits-all" failure in OA drug development. Conclusion: The central message of this review is that the inconsistent efficacy of anti-inflammatory therapies in OA reflects a patient-selection problem more than a failed target: agents tested in unselected populations, including most anti-cytokine biologics, have not relieved pain, whereas signals emerge for MTX in patients with an inflammatory phenotype. Stratifying patients by imaging-defined synovitis or effusion and inflammatory biomarkers is therefore the key unmet need, and phenotype-driven trial design-rather than new molecular targets alone-offers the most promising path to effective inflammation-targeted treatment of OA pain.
Key Findings
1
Intra-articular treatments and stratification using imaging-defined synovitis, effusion, and inflammatory biomarkers may improve therapeutic success.
2
Methotrexate shows promise for reducing pain and stiffness, particularly among patients with an inflammatory osteoarthritis phenotype.
3
Osteoarthritis heterogeneity likely explains inconsistent anti-inflammatory treatment efficacy and necessitates phenotype-driven therapeutic strategies.
4
TNF-α inhibition with adalimumab and IL-1 blockade with lutikizumab largely failed to meet primary pain endpoints in unselected osteoarthritis populations.
5
The review argues that patient selection and phenotype-driven trial design, rather than only identifying new molecular targets, are central unmet needs in osteoarthritis drug development.
Research Object
osteoarthritis, particularly patients with inflammatory phenotypes characterized by synovitis or effusion
Research Subject
the phenotype-dependent efficacy of anti-inflammatory therapies in relieving osteoarthritis pain and stiffness, including the role of patient stratification by synovitis, effusion, and inflammatory biomarkers
Publication Details
Publication Date
2026-10-01
Journal
Publisher
ISSN
Cited by
1
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee2020
Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 20212023
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee2020
Pain Reduction With Oral Methotrexate in Knee Osteoarthritis2024
Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis: A Randomized Clinical Trial2025